Related Experiment Video
Updated: Apr 19, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and
Gordon W Moe1, Justin A Ezekowitz2, Eileen O'Meara3
1St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Insights
The 2014 Canadian Cardiovascular Society Heart Failure Guidelines Update recommends investigating anemia, testing natriuretic peptides in chronic heart failure, and considering new treatments like mineralocorticoid receptor antagonists and angiotensin receptor/neprilysin inhibitors.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Heart failure management requires updated clinical practice guidelines.
- Recent advancements necessitate revisions in treatment protocols.
Purpose of the Study:
- To update the 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines.
- To provide recommendations on anemia, biomarkers, and clinical trials in heart failure management.
Main Methods:
- Review of current evidence and clinical trial data.
- Expert consensus on management strategies for heart failure patients.
Main Results:
- Investigate reversible causes of anemia in heart failure patients.
- Perform natriuretic peptide testing for chronic stable heart failure.
- Consider mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction and angiotensin receptor/neprilysin inhibitors for heart failure with reduced ejection fraction.
Conclusions:
- The 2014 update provides practical tips and recommendations for clinicians.
- Updated guidelines aim to improve patient outcomes in heart failure management.
Abstract:
The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Update provides discussion on the management recommendations on 3 focused areas: (1) anemia; (2) biomarkers, especially natriuretic peptides; and (3) clinical trials that might change practice in the management of patients with heart failure. First, all patients with heart failure and anemia should be investigated for reversible causes of anemia. Second, patients with chronic stable heart failure should undergo natriuretic peptide testing. Third, considerations should be given to treat selected patients with heart failure and preserved systolic function with a mineralocorticoid receptor antagonist and to treat patients with heart failure and reduced ejection fraction with an angiotensin receptor/neprilysin inhibitor, when the drug is approved. As with updates in previous years, the topics were chosen in response to stakeholder feedback. The 2014 Update includes recommendations, values and preferences, and practical tips to assist the clinicians and health care workers to best manage patients with heart failure.
Related Concept Videos
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Cardiomyopathy VI: Nursing Management
Heart Failure IV: Classification and Diagnostic Evaluation

